CopyFind
Sitazit-M 50mg/1000mg Tablet
medicine 📍 IN

Sitazit-M 50mg/1000mg Tablet

145,00 ₹

Analogs of Sitazit-M 50mg/1000mg Tablet

Find cheaper analogs and generic equivalents for Sitazit-M 50mg/1000mg Tablet.

Ingredients

Substanță activă: Sitagliptin; Metformin


Prezentare produs

About Sitazit-M

Sitazit-M is a medication containing the active ingredient Sitagliptin, classified as Dipeptidyl Peptidase 4 Inhibitor. Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type 2 diabetes. It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

Key Benefits & Uses

  • Used for: 1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a.
  • Use only as directed on the product label or by a healthcare professional.
  • Follow the authorised product information for dosing and duration of use.

Active Ingredient & Action

Sitagliptin, the active ingredient in Sitazit-M, belongs to the Dipeptidyl Peptidase 4 Inhibitor class. 1 INDICATIONS AND USAGE ZITUVIMET is a combination of sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Inactive ingredients: not listed in source data.

Important Notes

Always read and follow the label instructions carefully before taking Sitazit-M. If you have any underlying medical conditions, are taking other medicines, or are pregnant or breastfeeding, consult a doctor or pharmacist before use. Do not exceed the recommended dose on the package and do not use Sitazit-M for extended periods without medical advice.

Find in Pharmacies

Compare local prices and distance for Sitazit-M 50mg/1000mg Tablet.

Visitor ratings

Help others by rating how useful this product page is.

No ratings yet — be the first.